Challenges in the Management of Acute Severe Ulcerative Colitis in a Patient With Guillain-Barré Syndrome Associated With Infliximab
Lay Summary Despite being a rare adverse event, Guillain-Barré syndrome should be a differential diagnosis in patients taking tumor necrosis factor alpha (TNF-α) inhibitors who develop neurological events. Ustekinumab seems to be a safe option after TNF-α inhibitors in these patients.
Authors
- José Araújo
- Tânia Carvalho (ORCID: https://orcid.org/0000-0002-9108-5489)
- Bruno Arroja
- Dália Fernandes (ORCID: https://orcid.org/0000-0003-3066-1371)
- Joana Pinto (ORCID: https://orcid.org/0000-0001-9719-8364)
- Raquel Gonçalves (ORCID: https://orcid.org/0000-0002-5930-8611)
Institutions
- Unidade Hospitalar de Bragança (PT)
Publication Details
- Journal
- Inflammatory Bowel Diseases
- Published
- 2024-09-28
- DOI
- https://doi.org/10.1093/ibd/izae235
- Primary Topic
- Peripheral Neuropathies and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00